Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders

Key facts

Sponsor

Cytonet GmbH & Co. KG

Principal Investigator

Georg Hoffmann, Prof.

University Children's Hospital

Intervention

Human Heterologous Liver Cells(biological)

Enrollment

12 enrolled

Eligibility

5 years · All sexes

Timeline

2008 – 2015

Study locations (2)

• University Children's Hospital, Heinrich-Heine University, Düsseldorf, Germany
• University Children's Hospital, Heidelberg, Germany

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Ornithine transcarbamylase deficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06805695
  Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
  iECURE, Inc.
• RECRUITINGPHASE2NCT06488313
  A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
  Arcturus Therapeutics, Inc.
• RECRUITINGPHASE1, PHASE2NCT06255782
  An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
  iECURE, Inc.
• RECRUITINGPHASE1, PHASE2NCT05092685
  Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn
  University College, London
• ACTIVE NOT RECRUITINGPHASE3NCT05345171
  Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
  Ultragenyx Pharmaceutical Inc
• RECRUITINGNCT04908319
  Hepatic Histopathology in Urea Cycle Disorders
  Baylor College of Medicine
• ACTIVE NOT RECRUITINGNCT04612764
  Liver Disease in Urea Cycle Disorders
  Baylor College of Medicine
• ACTIVE NOT RECRUITINGNCT03636438
  Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
  Ultragenyx Pharmaceutical Inc

See all trials for Ornithine transcarbamylase deficiency →